Drug intelligence / Profile preview

DWP DN-63

Development stage: Unknown
Lead developer: Daewoo Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWP DN-63 is a clinical-stage drug candidate developed by Daewoo Pharma (대우제약) for the treatment of peptic ulcer disease. Currently in Phase 2 clinical development, it is part of the company's gastrointestinal research portfolio. While specific details regarding its molecular target or mechanism of action have not been publicly disclosed in the company's pipeline, it is being developed as a therapeutic option for acid-related gastric disorders. It is distinct from other peptic ulcer projects in the Daewoo Pharma pipeline, such as DWP DT-2402 (Phase 3) and DWP DT-2502 (Formulation).

Beyond the preview

Go deeper on DWP DN-63.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWP DN-63.

Explore the full profile